Modus Therapeutics Holding AB (publ) (MODTX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Välkommen till dagens livesända intervju från Modus Therapeutics. Vi har haft lite ljudbekymmer här inför sändningen så jag hoppas att det ska funka men jag kan inte garantera det. Vi får utgå från det vi har och hoppas på det bästa helt enkelt. Med mig i valigåring idag har jag med mig John Öd, VD. Han ska kommentera bokslutet för 2025 som presenterades i förra veckan. Välkommen John. Thank you, Martin. Thank you to everyone who listened in and who will be here later. If we go to the report, you describe the year as a year when Modus went from planning to implementation. What milestones would you like to lift up here in 2025? Ja, man kan ju faktiskt summera det som att det har handlat om klinisk leverans och finansiell stabilisering. Vi tittar tillbaka. In 2025, it will be about preparing our proof-of-concept study in patients with anemia. During 2025, we will be able to activate the multiple dose proof-of-concept part. of the study in patients. And there are a lot of milestones. One of which was that we were approved within a predetermined time to start dosing the patients already in 2025 and that we also actually managed to dose the first patient before the start of 2025. In terms of delivery, we have kept the plan exactly according to the preparations that we did during 2024 and 2021. And at the same time, between part 1 and part 2, we secured an overdraft for the trial selection, which gave us the opportunity to take this to the final result, the proof concept. If we look at the most important goals and values for the CKD Anemi study here in 2026, what data do you want to have on the table at the next year's shift, so to speak? If you look at a proof of concept, it is just a way to distinguish from more verifying clinical evidence, that is, we do not need regist...